(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 September 2004 (02.09.2004)

PCT

(10) International Publication Number
WO 2004/073716 A1

(51) International Patent Classification[7]: A61K 31/55, A61P 9/00, C07D 223/16

(21) International Application Number: PCT/JP2004/002085

(22) International Filing Date: 23 February 2004 (23.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/448,878 24 February 2003 (24.02.2003) US

(71) Applicant *(for all designated States except US)*: **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 9, Kandatsukasa-cho 2-chome, Chiyoda-ku, Tokyo 101-8535 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **OZAKI, Atsushi** [JP/JP]; 51-48, Tainohama-aza-nishinosu, Kitajima-cho, Itano-gun, Tokushima 771-0204 (JP). **MAKI, Yosuke** [JP/JP]; 5-18-10-103, Onoharahigashi, Mino-shi, Osaka 562-0031 (JP). **SATO, Osamu** [JP/JP]; 3-5-11-201, Chokojikita, Toyonaka-shi, Osaka 561-0875 (JP). **YAMAMURA, Yoshitaka** [JP/JP]; 45-16, Nakamura-Aza-Myojinshita, Kitajima-cho, Itano-gun, Tokushima 771-0203 (JP).

(74) Agents: **KAWAMIYA, Osamu** et al.; Aoyama & Partners Imp Building, 3-7, Shiromi 1-chome, Chuo-ku, Osaka-shi, Osaka 540-0001 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declaration under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/073716 A1

(54) Title: METHOD FOR TREATING SEVERE HEART FAILURE AND MEDICAMENT THEREFOR



(1)

(57) Abstract: A method for treating severe heart failure, comprising administering to a patient an effective amount of a benzazepine compound (1): wherein R_1 is H or halogen, R_2 is OH, or $-NR_5R_6$ (R_5 and R_6 are H or lower alkyl, R_3 is H, halogen, lower alkyl, or lower alkoxy, R_4 is halogen, lower alkyl or lower alkoxy, or a salt thereof, and a pharmaceutical composition containing the benzazepine compound (1) or a salt thereof and use of the compound (1) or a salt thereof for preparing a medicament for treatment of severe heart failure.